MedTrace Logo

Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)

NCT01201694 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2015-01-08

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable doses of surface-controlled water dispersible curcumin (curcumin) that can be given to patients with advanced cancer. The safety of this drug will also be studied.

Conditions

Interventions

DRUG

Surface-Controlled Water Soluble Curcumin

Starting dose 100 mg by mouth two times a day of a 28 day cycle.

DRUG

Surface-Controlled Water Soluble Curcumin MTD

Dose will be maximum tolerated dose (MTD) from Arm 1.

Sponsors & Collaborators

  • Gateway for Cancer Research

    collaborator OTHER

  • Theravalues, Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • David S. Hong, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01201694 on ClinicalTrials.gov